About: Certolizumab pegol

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Certolizumab pegol Goto Sponge NotDistinct Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type:

http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FCertolizumab_pegol&graph=http%3A%2F%2Fdbpedia.org&graph=http%3A%2F%2Fdbpedia.org

Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. It is on the World Health Organization's List of Essential Medicines.

Attributes	Values
rdf:type	Thing dul:ChemicalObject chemical substance Pill (pharmacy) yago:WikicatAntibodies yago:WikicatBelgianInventions monoclonal antibody yago:WikicatMonoclonalAntibodies yago:Ability105616246 yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Cognition100023271 yago:Compound114818238 yago:Creativity105624700 yago:Invention105633385 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:PsychologicalFeature100023100 yago:Relation100031921 drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:label	سرتوليزوماب بيغول (ar) Certolizumab pegol (ca) Certolizumab pegol (de) Certolizumab pegol (en) Certolizumab pegol (fr) Certolizumab pegol (it) セルトリズマブペゴル (ja) Certolizumab pegol (pl) Цертолизумаб пегол (ru)
rdfs:comment	El certolizumab pegol (CDP870, comercialitzat com a Cimzia) és un anticòs monoclonal terapèutic contra el factor de necrosi tumoral alfa (TNF-α). Aquest anti-TNF s'usa per al tractament de la malaltia de Crohn i l'artritis reumatoide. Fabricat per UCB, amb el nom de Cimzia. (ca) سيرتوليزوماب بيجول (Certolizumab pegol) (CDP870 والاسم التجاري سيمزيا)، هو مضاد حيوي وحيد النسيلة تصنعه يو سي بي (UCB) لعلاج داء كرون والتهاب المفاصل الرثياني. (ar) Certolizumab pegol (INN) oder kurz Certolizumab (Handelsname Cimzia; Hersteller UCB) ist ein Fab-Fragment eines rekombinanten, humanisierten monoklonalen Antikörpers, der an Polyethylenglycol konjugiert wurde (siehe auch PEGylierung). Der Arzneistoff wirkt als TNF-Blocker und wird zur Behandlung der entzündlichen Darmerkrankung Morbus Crohn sowie bei rheumatoider Arthritis und Psoriasis eingesetzt. (de) Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. It is on the World Health Organization's List of Essential Medicines. (en) Le Certolizumab pegol est un anticorps monoclonal dirigé contre le TNF alpha. Il est dit « pegol » car il est lié à du polyéthylène glycol. (fr) Il certolizumab pegolo CDP870, nome commerciale Cimzia è un farmaco anticorpo monoclonale prodotto dalla UCB principalmente per il trattamento della Malattia di Crohn e dell'Artrite reumatoide. Il certolizumab pegol agisce sul TNF-α; è un frammento PEGilato di un anticorpo monoclonale umanizzato. (it) セルトリズマブペゴル（certolizumab pegol, CDP870, tradename, Cimzia）は、UCBが製造するクローン病および関節リウマチの治療用モノクローナル抗体由来製剤である。日本においては、アステラス製薬が導入し、シムジア皮下注200mgとして2013年3月8日より販売を開始した。 (ja) Certolizumab pegol (CDP 870) – humanizowany fragment Fab' przeciwciała monoklonalnego skierowanego przeciwko TNF-α, połączony z glikolem polietylenowym (czyli poddany tzw. ). Preparat wytwarzany jest na drodze fermentacji mikrobiologicznej. Proces pegylacji ma na celu wydłużenie okresu półtrwania leku. (pl) Цертолизумаб пегол — лекарственный препарат, фрагмент моноклонального антитела, ингибитор фактора некроза опухоли. Одобрен для применения: США (2008). (ru)
foaf:depiction
dcterms:subject	Biotechnology Immunosuppressants World Health Organization essential medicines TNF inhibitors Disease-modifying antirheumatic drugs Monoclonal antibodies Belgian inventions
Wikipage page ID	6352441 (xsd:integer)
Wikipage revision ID	1098343327 (xsd:integer)
Link from a Wikipage to another Wikipage	Ankylosing spondylitis Rheumatoid arthritis Biotechnology Crohn's disease Psoriatic arthritis Monoclonal antibody Macrogol Committee for Medicinal Products for Human Use Tumor necrosis factor alpha UCB (company) Immunosuppressants World Health Organization essential medicines European Medicines Agency Food and Drug Administration Food and Drug Administration (United States) Fragment antigen-binding TNF inhibitors Disease-modifying antirheumatic drugs Monoclonal antibodies Belgian inventions Kidney Axial spondyloarthritis Placebo TNF alpha TNF inhibitor WHO Model List of Essential Medicines PEGylated
Link from a Wikipage to an external page	https://druginfo.nlm.nih.gov/drugportal/name/certolizumab%20pegol
sameAs	Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol Certolizumab pegol

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software